| Low-NLR group (n = 162) | High-NLR group (n = 162) | P value |
---|---|---|---|
Age, years,mean ± SD | 41.65 ± 16.58 | 45.15 ± 17.32 | 0.064 |
Male sex, no. (%) | 39 (24.1%) | 54 (33.3%) | 0.065 |
Hypertension, no. (%) | 18 (11.1%) | 27 (16.7%) | 0.148 |
Diabetes, no. (%) | 9 (5.6%) | 10 (6.2%) | 0.813 |
Initial EDSS, median (IQR) | 4 (3, 5) | 4 (5, 7) | < 0.001 |
Initial symptoms (%) | Â | Â | Â |
Optic neuritis, no. (%) | 39 (24.1%) | 35 (21.6%) | 0.597 |
Acute myelitis, no. (%) | 75 (46.3%) | 75 (46.3%) | – |
Optic neuritis with Acute myelitis, no. (%) | 16 (9.9%) | 21 (13.0%) | 0.382 |
LETM, no. (%) | Â | Â | 0.062 |
Not tested | 54 (33.3%) | 50 (30.9%) | Â |
Yes | 75 (46.3%) | 90 (55.6%) | Â |
No | 33 (20.4%) | 22 (13.5%) | Â |
Anti-AQP4 antibody, no. (%) | Â | Â | 0.337 |
Not tested | 42 (25.9%) | 11 (6.8%) | Â |
Negative | 44 (27.2%) | 47 (29.0%) | Â |
Positive | 76 (46.9%) | 104 (64.2%) | Â |
Corticosteroids, no. (%) | 155 (95.7%) | 155 (95.7%) | – |
Immunoglobulins, no. (%) | 14 (8.6%) | 19 (11.7%) | 0.358 |
Immunosuppressants, no. (%) | 52 (32.1%) | 59 (36.4%) | 0.245 |
Blood platelet count (× 109/L), median (IQR) | 214 (178,256) | 227.5 (185.75, 284) | 0.147 |
Neutrophil count (× 109/L), median (IQR) | 3.2 (2.59, 4.15) | 6.01 (4.45, 8.40) | < 0.001 |
Lymphocyte count (× 109/L), median (IQR) | 2 (1.7, 2.4) | 1.2 (0.86, 1.71) | < 0.001 |
Monocyte count (× 109/L), median (IQR) | 0.45 (0.36, 0.59) | 0.5 (0.34, 0.65) | 0.428 |
NLR, median (IQR) | 1.63 (1.28, 2.05) | 4.28 (3.01, 6.72) | < 0.001 |
PLR, median (IQR) | 104.63(82.54, 135.62) | 182.20 (122.06, 252.75) | < 0.001 |
LMR, median (IQR) | 4.4 (3.4, 5.53) | 2.77 (1.20, 4.22) | < 0.001 |
Follow-up EDSS, median (IQR) | 2 (2, 3) | 4 (3, 6) | < 0.001 |
Relapse, no. (%) | 33(20.4%) | 104(64.2%) | < 0.001 |
Interval, days, median (IQR) | 1311 (959, 1777) | 1233 (809, 1751) | 0.223 |
DMT, no. (%) | 21(13.0%) | 24(14.8%) | 0.63 |
Azathioprine | 9(5.6%) | 12(7.4%) | 0.498 |
Mycophenolate mofetil | 7(4.3%) | 4(2.5%) | 0.357 |
Cyclophosphamide | 2(1.2%) | 3(1.9%) | 1 |
Intravenous immunoglobulin | 1(0.6%) | 2(1.2%) | 1 |
Rituximab | 1(0.6%) | 2(1.2%) | 1 |